Table 4.
Studies assessing the use of metabolic tumour volume (MTV) and total lesion glycolysis (TLG) and Hodgkin lymphoma (HL)
| Author | Year | Patient no. | Stage | Treatment | Events (follow-up cut-off) | Segmentation threshold | MTV/TLG | Cut-off | Predictive univariate analysis HR (95% CI), |
Predictive multivariate analysis HR (95% CI), parameters included in multivariate analysis |
|||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| I/II | III/IV | PFS | OS | PFS | OS | ||||||||
| Albano [13]a | 2020 |
123 Elderly |
36 | 87 | ABVD, BEACOPP, R-CHOP, ± RT, RT |
Relapse: 51 Died: 37 (no defined cut-off) |
41% SUVmax | MTV | 89 ml | 0.531 (0.294–0.908) | NS | 0.555 (0.249–0.965) | NR |
| TLG | 2199 g | 0.544 (0.240–0.963) | NS | 0.602 (0.111–0.989) | NR | ||||||||
| Lue [34] | 2019 | 42 | 20 | 22 | Anthracycline-based chemotherapy ± RT |
Relapse: 12 Died: 9 (5-year) |
41% SUVmax | MTV | 183 ml | 4.495 (1.434–14.09) | 4.500 (1.205–16.81) | NS | NS |
| Mettler [35] | 2019 | 310 | 310 | eBEACOPP (4 or 6 cycles) |
PFS: 16 events OS: 7 events (no defined cut-off) |
41% SUVmax, >2.5 SUV, Liver SUVmax, Liver SUVmean | MTV41% | NR | NS | NS | NS | NS | |
| MTV2.5 | NR | NS | NS | NS | NS | ||||||||
| MTVlmax | NR | NS | NS | NS | NS | ||||||||
| MTVlmean | NR | NS | NS | NS | NS | ||||||||
| Akhtari. [12] | 2018 | 267 | 267 | 0 | ABVD ± RT |
Relapse/refractor = 27 (5-year) |
≥2.5 SUV or manually contour | MTV2.5 | Continuous | 1.00 (1.0007–1.0025) | NR | NR | NR |
| TLG2.5 | 1703 g | 1.00 (1.0001–1.0004 | NR | NR | NR | ||||||||
| MTVman | NR | 1.00 (1.0006–1.0019) | NR | NR | NR | ||||||||
| TLGman | NR | 1.00 (1.0001–1.0004) | NR | NR | NR | ||||||||
| Cottereau [21] | 2018 | 258 | 258 | ABVD ± RT |
PFS: 27 events OS: 12 (5-year) |
≥2.5 SUV | MTV | 147 ml | 5.2 (1.8–14.7) | 7.2 (1.6–33.4) | Sig with individual factors, EORTC, GHCS and NCCN | Sig with individual factors, EORTC, GHCS and NCCN | |
| Angelopoulou [14] | 2017 | 162 | 76 | 86 | ABVD ± BEACOPP, ± RT |
PFS: 81% OS: 93% (5-year) |
TLG from maximal largest diameter x SUVmax | TLG | <35, 35–100, <100 | 70 vs. 81 vs. 94% | NR | NR | NR |
| Kanoun [29] | 2015 | 59 | Anthracycline-based 4–6-8 cycles |
Relapse: 5 Died: 5 (no defined cut-off) |
41% SUVmax | MTV | 225 ml | 42 vs. 85% | NR | Sig when analysed with tumour change in SUVmax | NR | ||
| Song. [43] | 2013 | 127 | 127 | ABVD ± RT |
PFS: 85.8% OS: 88.2% (no defined cut-off) |
≥2.5 SUV | MTV | 198 ml | 10.707 (3.098–37.002) | 13.201 (2.975–58.579) |
13.008 (3.441–49.174) Age, B symptoms, mediastinal bulky disease |
15.831 (3.301–75.926 Age, B symptoms, mediastinal bulky disease |
|
| Tseng [46] | 2012 | 30 | 11 | 19 | Standford V, ABVD, VAMP, BEACOPP |
Relapse =6 Died: 4 (4-year) |
NR | MTV | NS | NS | NR | NR | |
NR not reported; NS not significant; Sig. significant; HR hazard ratio; CI confidence interval; PFS progressive free survival; OS overall survival; R-CHOP rituximab cyclophosphamide, doxorubicin hydrochloride, vincristine (Oncovin) and prednisolone; R-ACVBP Rituximab, Doxorubicin, Cyclophosphamide, Vindesine, Bleomycin, prednisolone; RT radiotherapy; ABVD doxorubicin (Adriamycin), bleomycin, vinblastine and dacarbazine; eBEACOPP escalated dose bleomycin, etoposide, doxorubicin (Adriamycin), cyclophosphamide, vincristine (Oncovin), procarbazine, and prednisone; VAMP vincristine, doxorubicin hydrochloride, methotrexate, prednisolone; EORTC European Organisation for Research and Treatment of Cancer; GHSC German Hodgkin lymphoma study group; NCCN National Comprehensive Cancer Network
aThe HRs presented as presented in the study but are inverse to the other HRs within the table